November-December 2005 - Volume 15 - Supplement 3
pp: 195-306

First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

KRISTENSEN, G. B.; VERGOTE, I.; STUART, G.; More

International Journal of Gynecological Cancer. 15:221, November-December 2005.

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial

PUJADE-LAURAINE, E.; DU BOIS, A.; GOUPIL, A.; More

International Journal of Gynecological Cancer. 15:222-223, November-December 2005.

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

DU BOIS, A.; SEHOULI, J.; LUND, B.; More

International Journal of Gynecological Cancer. 15:224-225, November-December 2005.